Toronto Dominion Bank
ALXN

Toronto Dominion Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

Toronto Dominion Bank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6,000
Closed -$588K – 1615
2019
Q3 		$588K Buy
+6,000
New +$676K ﹤0.01% 1020

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Toronto Dominion Bank's ALXN Position: Q3 2021 in Review

Toronto Dominion Bank sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 573,820 shares — an estimated $105M sold.

Toronto Dominion Bank first reported a position in ALXN in Q4 2013 and held it in 31 quarters. The position peaked at $105M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Toronto Dominion Bank reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Toronto Dominion Bank sold 573,820 Alexion Pharmaceuticals shares in Q3 2021, an estimated $105M.
  • Toronto Dominion Bank first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 31 quarters.
  • Toronto Dominion Bank's Alexion Pharmaceuticals position peaked at $105M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Toronto Dominion Bank's 13F filing for Q3 2021, filed 8 Nov 2021.